久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Technology

BeiGene's cancer therapy gets green light

By Liu Zhihua | chinadaily.com.cn | Updated: 2020-04-12 18:32
Share
Share - WeChat
Scientists discuss use of equipment at the central chemistry lab of BeiGene in Beijing in May 2017. [Photo provided to chinadaily.com.cn]

China's biotechnology company BeiGene Ltd announced on Saturday that its anti-PD-1 antibody tislelizumab, an immunotherapy, had received approval from the China National Medical Products Administration as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC), the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December.

The NMPA approval is based on the clinical results from a single-arm, multi-center pivotal Phase 2 trial of tislelizumab in patients in China and South Korea.

Among patients who were evaluable for response, with a minimum follow-up of 12 months and a median follow-up of 14 months, the objective response rate (ORR) as assessed by the independent review committee was 24.8 percent, and the complete response (CR) rate was 9.9 percent.

The newly approved indication, for patients suffering from locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, is the first in a solid tumor indication.

According to Ye Dingwei, vice-president of Fudan University Shanghai Cancer Center, patients with advanced UC have limited treatment options, and it is great that tislelizumab, a new immuno-oncology treatment, becomes available to them.

Supported by encouraging efficacy and safety results from the trial, tislelizumab is believed to bring significant benefits to the patients, he said.

The company also has a broad development program for tislelizumab that encompasses 15 potentially registration-enabling trials globally and in China, in indications including lung, liver, esophageal, gastric, nasopharyngeal, and MSI-H or dMMR cancers, in addition to classical Hodgkin's lymphoma and UC.

"This is our third new drug application approval in the past five months for our internally developed products, a tremendous accomplishment for a young biotechnology company like BeiGene and validation of the team's hard work," said John V. Oyler, the company's chairman, co-founder, and CEO.

"Our strategy for tislelizumab has always been to pursue a broad label and serve patients who are battling different types of cancer. With tislelizumab's first solid tumor approval, we are even more excited about the outlook for this immunotherapy than ever."

However, like other immune checkpoint inhibitors, tislelizumab could cause immune-related adverse reactions that mainly include pneumonitis, diarrhea and colitis, hepatitis, and endocrinopathies (hypothyroidism, hyperthyroidism and thyroiditis, adrenocortical insufficiency, hyperglycemia and type 1 diabetes mellitus), and skin adverse reactions. Occasionally, nephritis, pancreatitis, myocarditis, myositis, and other immune-related adverse reactions were also reported, the company said in a release.

Most common adverse reactions included rash, fatigue, and increased alanine aminotransferase.

The recommended dose of tislelizumab is 200 mg administered as an intravenous infusion every three weeks until disease progression or intolerable toxicity.

Tislelizumab is not approved for use outside China.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 亚洲国产精品久久日 | 国产极品精频在线观看 | 国产精品久久久精品视频 | 成人福利网站含羞草 | 欧美成人a级在线视频 | 国产免费久久 | 欧美性夜欢 | 韩国一级永久免费观看网址 | 性做爰片免费视频毛片中文i | 国产一级免费视频 | 欧美成人在线免费 | 日本亚洲欧美高清专区vr专区 | 全免费a级毛片免费毛视频 全午夜免费一级毛片 | 久久精品成人免费网站 | 韩国自拍偷自拍亚洲精品 | 成人欧美精品一区二区不卡 | 国产综合成人久久大片91 | 日韩一级在线视频 | 91精品视频在线播放 | 欧美jizzhd精品欧美高清 | 免费99视频有精品视频高清 | 日本在线www | 夜色sese| 久草视频资源站 | 91在线免费观看网站 | 日本aaaa特级毛片 | 亚洲一区网站 | 色综合加勒比 | 999久久 | 国产成人无精品久久久久国语 | 中文字幕亚洲在线 | 国产真实女人一级毛片 | 日韩在线观看视频免费 | aaaaaa精品视频在线观看 | 精品国产一区二区三区久久 | 婷婷的久久五月综合先锋影音 | 99精品久久久久久久免费看蜜月 | 国产在线更新 | 国产欧美久久久精品影院 | 国产成人cao在线 | 日韩字幕 |